Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Can HPV Selfy be considered as a clinically validated HPV test for use in cervical cancer screening?

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Differentieret implementering af HPVbaseret screening i dansk livmoderhalskræftscreening

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Frederique J Vink
  • Chris J L M Meijer
  • Albertus T Hesselink
  • Arno N Floore
  • Birgit I Lissenberg-Witte
  • Jesper H Bonde
  • Helle Pedersen
  • Kate Cuschieri
  • Ramya Bhatia
  • Mario Poljak
  • Anja Oštrbenk Valenčak
  • Peter Hillemanns
  • Wim G V Quint
  • Marta Del Pino
  • Gemma G Kenter
  • Renske D M Steenbergen
  • Daniëlle A M Heideman
  • Maaike C G Bleeker
Vis graf over relationer

INTRODUCTION: HSIL or CIN2/3 lesions in HPV-positive women <30 years have high spontaneous regression rates. To reduce overtreatment, biomarkers are needed to delineate advanced CIN lesions that require treatment. We analysed the FAM19A4/miR124-2 methylation test and HPV16/18 genotyping in HPV-positive women <30 years aiming to identify CIN2/3 lesions in need of treatment.

METHODS: A European multicentre retrospective study was designed evaluating the FAM19A4/miR124-2 methylation test and HPV16/18 genotyping in cervical scrapes of 1,061 HPV-positive women aged 15-29 years (690 ≤CIN1, 166 CIN2 and 205 CIN3+). A subset of 62 CIN2 and 103 CIN3 were immunohistochemically characterized by HPV E4 expression, a marker for a productive HPV infection and p16ink4a and Ki-67, markers indicative for a transforming infection. CIN2/3 lesions with low HPV E4 expression and high p16ink4a/Ki-67 expression were considered as non-productive, transforming CIN, compatible with advanced CIN2/3 lesions in need of treatment.

RESULTS: FAM19A4/miR124-2 methylation positivity increased significantly with CIN grade and age groups (<25, 25-29 and ≥30 years), while HPV16/18 positivity was comparable across age groups. FAM19A4/miR124-2 methylation positivity was HPV type independent. Methylation-positive CIN2/3 lesions had higher p16ink4a/Ki-67-immunoscores (p = 0.003) and expressed less HPV E4 (p = 0.033) compared with methylation-negative CIN2/3 lesions. These differences in HPV E4 and p16ink4a/Ki-67 expression were not found between HPV16/18-positive and non-16/18 HPV-positive lesions.

CONCLUSIONS: Compared with HPV16/18 genotyping, the FAM19A4/miR124-2 methylation test detects non-productive, transforming CIN2/3 lesions with high specificity in women <30 years, providing clinicians supportive information about the need for treatment of CIN2/3 in young HPV-positive women.

OriginalsprogEngelsk
Artikelnummerciac433
TidsskriftClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Sider (fra-til)1-21
Antal sider21
ISSN1058-4838
DOI
StatusE-pub ahead of print - 10 jun. 2022

Bibliografisk note

© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

ID: 78738887